Eli Lilly Settles Dispute Over Antibody Research Patents

Law360, New York (September 24, 2005, 12:00 AM EDT) -- In a sealed settlement agreement for recombinant protein technologies, drug maker Eli Lilly has ended infringement litigation against a European rival.

The settlement ends patent litigation initiated by Eli Lilly subsidiary Applied Molecular Evolution (AME) against German competitor MorphoSys AG in June 2001, alleging infringement of AME’s molecular evolution patents, in U.S. District Court for the District of Massachusetts.

California-based AME claimed MorphoSys, and its subsidiary MorphoSys USA, Inc., infringed the patents through its popular research product called the Human Combinatorial Antibody Library (HuCAL). The library...
To view the full article, register now.